E. Jason Abel, MD, FACS Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.
Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.
UW School of Medicine and Public Health
|Department of Urology|
Professional Certifications and Education
Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX
University of Utah, Salt Lake City, UT, UT
University of Utah, Salt Lake City, UT, UT
University of Texas Medical School, Houston, TX, 2003
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.
Klapperich ME Abel EJ Ziemlewicz TJ Best S Lubner MG Nakada SY Hinshaw JL Brace CL Lee FT Jr Wells SA .
Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology. 2017 Jul;284(1):272-280
[PubMed ID: 28076721]
Shapiro DD Abel EJ .
Editorial Comment. J Urol. 2017 Jun 19;
[PubMed ID: 28641080]
Wells SA Wong VK Wittmann TA Lubner MG Best SL Ziemlewicz TJ Hinshaw JL Lee FT Jr Abel EJ .
Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure? Abdom Radiol (NY). 2017 Jun;42(6):1773-1780
[PubMed ID: 28184961]
Best SL Abel EJ .
Editorial Comment. J Urol. 2017 May 17;
[PubMed ID: 28527306]
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM .
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017 May 2;
[PubMed ID: 28464520]
Tazeh NN Canter DJ Damodaran S Rushmer T Richards KA Abel EJ Jarrard DF Downs TM .
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer. 2017 Apr 27;3(2):89-94
[PubMed ID: 28516153]
Abel EJ Masterson TA Karam JA Master VA Margulis V Hutchinson R Lorentz CA Bloom E Bauman TM Wood CG Blute ML Jr .
Predictive Nomogram for Recurrence Following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 Apr 12;
[PubMed ID: 28411071]
Best SL Blute M Jr Lane B Abel EJ .
Surgical Treatment of 4-10 cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles. J Endourol. 2017 Apr;31(S1):S43-S47
[PubMed ID: 28326796]
Abel EJ Spiess PE Margulis V Master VA Mann M Zargar-Shoshtari K Borregales LD Sexton WJ Patil D Matin SF Wood CG Karam JA .
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Mar 6;
[PubMed ID: 28268170]
Wittmann TA Abel EJ .
Percutaneous biopsy in large, locally advanced or metastatic renal tumors. Urol Oncol. 2017 Mar;35(3):87-91
[PubMed ID: 27889280]
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF .
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One. 2017;12(2):e0172048
[PubMed ID: 28234906]
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ .
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 2017 Feb;100:139-144
[PubMed ID: 27667156]
Bauman TM Huang W Lee MH Abel EJ .
Neovascularity as a prognostic marker in renal cell carcinoma. Hum Pathol. 2016 Nov;57:98-105
[PubMed ID: 27436827]
Abel EJ .
Erratum to: Percutaneous biopsy facilitates modern treatment of renal masses. Abdom Radiol (NY). 2016 Oct;41(10):2087
[PubMed ID: 27259337]
Abel EJ .
Editorial Comment. Urology. 2016 Oct;96:113
[PubMed ID: 27561850]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ .
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology. 2016 Oct;96:93-98
[PubMed ID: 27339026]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ .
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep;118(3):399-407
[PubMed ID: 26589741]
Richards KA Abel EJ .
Surveillance following surgery for nonmetastatic renal cell carcinoma. Curr Opin Urol. 2016 Sep;26(5):432-8
[PubMed ID: 27467135]
Lubner MG Stabo N Abel EJ Del Rio AM Pickhardt PJ .
CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes. AJR Am J Roentgenol. 2016 Jul;207(1):96-105
[PubMed ID: 27145377]
Abel EJ Margulis V Bauman TM Karam JA Christensen WP Krabbe LM Haddad A Golla V Wood CG .
Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun;117(6B):E87-94
[PubMed ID: 26305276]